What are the major manufacturers of pazopanib/pazopanib?

Pazopanib is an oral multi-target tyrosine kinase inhibitor (TKI) mainly used to treat advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS). The drug was originally developed by GlaxoSmithKline (GSK) and has been approved for marketing in many countries. GSK manufactures and sells the drug globally under the trade name VOTRIENT.

In2015, GSK reached a deal with Novartis to transfer some of its oncology products, including pazopanib, to Novartis. Therefore, the main manufacturer and marketer of pazopanib is currently Novartis Pharmaceuticals, which is responsible for the marketing of the drug in many countries.

In addition, since pazopanib has been approved by drug regulatory agencies in many countries and regions, including the USFDA, the European EMA and the Chinese NMPA, some pharmaceutical companies have also obtained authorization to produce generic drugs. Currently, some pharmaceutical companies in India, Bangladesh and other countries, such as NATCO Pharma, Cipla, Beacon Pharmaceuticals, etc., also produce pazopanib generics and supply them to the market at lower prices.

In the Chinese market, imported pazopanib is mainly sold by Novartis Pharmaceuticals, and some domestic pharmaceutical companies may apply to produce generic drugs to reduce the financial burden on patients. However, when choosing generic drugs, patients should give priority to drugs approved by the State Food and Drug Administration to ensure efficacy and safety.

Reference materials:https://www.votrient.com/